Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul;16(3):170-84.
doi: 10.5863/1551-6776-16.3.170.

Neonatal pharmacology: extensive interindividual variability despite limited size

Cuneyt Tayman, Maisa Rayyan, Karel Allegaert

Neonatal pharmacology: extensive interindividual variability despite limited size

Cuneyt Tayman et al. J Pediatr Pharmacol Ther. 2011 Jul.

Abstract

Providing safe and effective drug therapy to neonates requires knowledge of the impact of development on the pharmacokinetics and pharmacodynamics of drugs. Although maturational changes are observed throughout childhood, they are most prominent during the first year of life. Several of these processes overlap, making development an extremely dynamic system in the newborn compared with that in infants, children, or adults. Changes in body composition and porportions, liver mass, metabolic activity, and renal function collectively affect the pharmacokinetic behavior of medications. Instead of simply adapting doses by scaling adult or pediatric doses on the basis of a patient's weight and/or body surface area, integrated knowledge of clinical maturation and developmental pharmacology is critical to the safe and effective use of medications in neonates. Unfortunately, the effects of human ontogeny on both pharmacokinetics and pharmacodynamics have not been well established in these early stages of life, and information regarding the influence of developmental changes on the pharmacodynamics of medications is even more limited. Theoretically, age-dependent variations in receptor number and affinity for drugs have significant potential to influence an individual's response to drug therapy. In this review, some of the relevant covariates of pharmacokinetics and pharmacodynamics in neonates are reviewed and illustrated based on the published literature.

Keywords: developmental pharmacology; neonate; pharmacodynamic; pharmacokinetic.

PubMed Disclaimer

References

    1. Avanel S, Bomkratz A, Dassieu G, et al. The incidence of prescription without marketing product license in a neonatal intensive care unit. Arch Pediatr. 2000;7(2):143–147. - PubMed
    1. Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for drug Investigation in Children. BMJ. 2000;320(7227):79–82. - PMC - PubMed
    1. Van den Anker J. Managing drug safely. Semin Fetal Neonatal Med. 2005;10(1):73–81. - PubMed
    1. Rakhmanina NY, van den Anker JN. Pharmacological research in pediatrics: from neonates to adolescents. Adv Drug Deliv Rev. 2006;58(1):4–14. - PubMed
    1. Blumer JL, Reed MD. Principle of neonatal pharmacology. In: Yaffe SJ, Aranda JV, editors. Neonatal and Pediatric Pharmacology. 3rd ed. Philadelphia: WB Saunders & Co; 2005. pp. 146–158.

LinkOut - more resources